Recruiting Scleroderma Studies in Palo Alto
Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung ...
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis...
About Scleroderma Clinical Trials in Palo Alto
Scleroderma is an autoimmune connective tissue disease characterized by hardening and tightening of the skin and connective tissues. Systemic sclerosis can also affect internal organs including lungs, kidneys, and heart. Treatment is directed at specific symptoms and organ involvement.
There are currently 2 scleroderma clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 421 participants. Research is being sponsored by Scleroderma Research Foundation, Inc., Kyverna Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Scleroderma Clinical Trials in Palo Alto — FAQ
Are there scleroderma clinical trials in Palo Alto?
Yes, there are 2 scleroderma clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Palo Alto?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.
Are clinical trials in Palo Alto free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.
What scleroderma treatments are being tested?
The 2 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for scleroderma.
Data updated March 2, 2026 from ClinicalTrials.gov